(Q35891544)

11 August 2017

1 reference

title

Combination therapy for multiple sclerosis: the treatment strategy of the future? (English)

1 reference

11 August 2017

0 references

Bianca Weinstock-Guttman

series ordinal

1

object named as

Bianca Weinstock-Guttman

1 reference

11 August 2017

Rohit Bakshi

2

1 reference

11 August 2017

language of work or name

1 reference

1 January 2004

1 reference

11 August 2017

1 reference

11 August 2017

volume

18

1 reference

11 August 2017

issue

12

1 reference

11 August 2017

page(s)

777-792

1 reference

Statins and their potential targets in multiple sclerosis therapy

11 August 2017

cites work

1 reference

12 December 2020

Combination therapy with glatiramer acetate (copolymer-1) and a type I interferon (IFN-alpha) does not improve experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years

1 reference

12 December 2020

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadi

1 reference

12 December 2020

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

1 reference

12 December 2020

The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. The Canadian Cooperative Multiple Sclerosis Study Group

1 reference

12 December 2020

Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination

1 reference

12 December 2020

Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS.

1 reference

12 December 2020

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

High-dose intravenous methylprednisolone in the treatment of multiple sclerosis: clinical-immunologic correlations

1 reference

12 December 2020

Glucocorticosteroid therapy for multiple sclerosis: a critical review

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

12 December 2020

Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion

1 reference

12 December 2020

Matrix metalloproteinases and neuroinflammation in multiple sclerosis

1 reference

12 December 2020

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

1 reference

12 December 2020

Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol).

1 reference

12 December 2020

A phase II study of i.v. methylprednisolone in secondary-progressive multiple sclerosis

1 reference

12 December 2020

Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans

1 reference

12 December 2020

Combination therapy with interferon beta-1b and azathioprine in secondary progressive multiple sclerosis. A two-year pilot study.

1 reference

12 December 2020

Fat chance of immunomodulation

1 reference

12 December 2020

A randomised placebo controlled exploratory study of vitamin B-12, lofepramine, and L-phenylalanine (the "Cari Loder regime") in the treatment of multiple sclerosis.

1 reference

12 December 2020

Effect of low saturated fat diet in early and late cases of multiple sclerosis.

1 reference

12 December 2020

Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis

1 reference

12 December 2020

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

1 reference

12 December 2020

Human herpesvirus 6 and Chlamydia pneumoniae as etiologic agents in multiple sclerosis - a critical review

1 reference

12 December 2020

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS.

1 reference

12 December 2020

Efficient central nervous system remyelination requires T cells

1 reference

12 December 2020

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group

1 reference

12 December 2020

Statins as potential therapeutic agents in neuroinflammatory disorders

1 reference

12 December 2020

Low-dose oral methotrexate in chronic progressive multiple sclerosis: analyses of serial MRIs

1 reference

12 December 2020

Treatment of multiple sclerosis with the pregnancy hormone estriol

1 reference

12 December 2020

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

1 reference

12 December 2020

Multiple paths towards repair in multiple sclerosis

1 reference

12 December 2020

MRI changes in multiple sclerosis following treatment with lofepramine and L-phenylalanine.

1 reference

12 December 2020

A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica

1 reference

12 December 2020

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

1 reference

12 December 2020

The role of integrins in immune-mediated diseases of the nervous system

1 reference

12 December 2020

Dietary polyunsaturated fatty acids and inflammatory mediator production

1 reference

12 December 2020

Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results

1 reference

12 December 2020

Overview of azathioprine treatment in multiple sclerosis

1 reference

12 December 2020

Acyclovir treatment of relapsing-remitting multiple sclerosis. A randomized, placebo-controlled, double-blind study.

1 reference

12 December 2020

An open-label safety and drug interaction study of natalizumab (Antegren) in combination with interferon-beta (Avonex) in patients with multiple sclerosis

1 reference

12 December 2020

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

1 reference

12 December 2020

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

1 reference

12 December 2020

Immune regulatory properties and interactions of copolymer-I and beta-interferon 1a in multiple sclerosis

1 reference

12 December 2020

Effects of combination therapy of beta-interferon 1a and prednisone on serum immunologic markers in patients with multiple sclerosis

1 reference

12 December 2020

Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy

1 reference

12 December 2020

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

1 reference

12 December 2020

Interferon beta results in immediate reduction of contrast-enhanced MRI lesions in multiple sclerosis patients followed by weekly MRI.

1 reference

12 December 2020

Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

T2 hypointensity in the deep gray matter of patients with multiple sclerosis: a quantitative magnetic resonance imaging study

1 reference

12 December 2020

Inhibition of autoimmune encephalomyelitis by a tetracycline.

1 reference

12 December 2020

Interferon beta in the treatment of multiple sclerosis: mechanisms of action

1 reference

12 December 2020

Role of nitric oxide in inflammation-mediated neurodegeneration.

1 reference

12 December 2020

Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis

1 reference

12 December 2020

An open-label trial of combination therapy with interferon beta-1a and oral methotrexate in MS

1 reference

12 December 2020

Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials

1 reference

12 December 2020

Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.

1 reference

12 December 2020

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

12 December 2020

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

1 reference

12 December 2020

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

1 reference

12 December 2020

Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis

1 reference

12 December 2020

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

12 December 2020

Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis

1 reference

12 December 2020

10.2165/00023210-200418120-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

11 August 2017

1026579868

0 references

1 reference